Table 2 The most advanced biological preparations used in asthma
From: Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly
Drug | Target | Function |
|---|---|---|
Atrakincept | Anti-IL4 | Binds IL-4 thus blocking the interaction with its receptor. Reduces the proliferation of Th2 lymphocytes. Phase II |
Pascolizumab | ||
Benralizumab | Anti IL-5 receptor | Reduces the proliferation and activation of eosinophils. Phase II |
Daclizumab | Anti CD-25 | Blocks the receptor for IL-2 |
Kerliximab | Anti CD-4 | Reduces the proliferation of CD4+ lymphocytes. Phase II |
Mepolizumab | Anti IL-5 | Reduces the proliferation and activation of eosinophils. Phase III |
Reslizumab | ||
Omalizumab | Anti IgE | Complexes circulating IgE and impedes their binding to receptor. Commercialized |
Pitakinra | IL-4 mutein | Competes with IL-4 and IL-13 receptor. Phase III |